REVISE : Re-Evaluating the Inhibition of Stress Erosions in the ICU: a randomised trial protocol
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
INTRODUCTION: The Re-Evaluating the Inhibition of Stress Erosions (REVISE) Trial aims to determine the impact of the proton pump inhibitor pantoprazole compared with placebo on clinically important upper gastrointestinal (GI) bleeding in the intensive care unit (ICU), 90-day mortality and other endpoints in critically ill adults. The objective of this report is to describe the rationale, methodology, ethics and management of REVISE.
METHODS AND ANALYSIS: REVISE is an international, randomised, concealed, stratified, blinded parallel-group individual patient trial being conducted in ICUs in Canada, Australia, Saudi Arabia, UK, US, Kuwait, Pakistan and Brazil. Patients≥18 years old expected to remain invasively mechanically ventilated beyond the calendar day after enrolment are being randomised to either 40 mg pantoprazole intravenously or an identical placebo daily while mechanically ventilated in the ICU. The primary efficacy outcome is clinically important upper GI bleeding within 90 days of randomisation. The primary safety outcome is 90-day all-cause mortality. Secondary outcomes include rates of ventilator-associated pneumonia, Clostridioides difficile infection, new renal replacement therapy, ICU and hospital mortality, and patient-important GI bleeding. Tertiary outcomes are total red blood cells transfused, peak serum creatinine level in the ICU, and duration of mechanical ventilation, ICU and hospital stay. The sample size is 4800 patients; one interim analysis was conducted after 2400 patients had complete 90-day follow-up; the Data Monitoring Committee recommended continuing the trial.
ETHICS AND DISSEMINATION: All participating centres receive research ethics approval before initiation by hospital, region or country, including, but not limited to - Australia: Northern Sydney Local Health District Human Research Ethics Committee and Mater Misericordiae Ltd Human Research Ethics Committee; Brazil: Comissão Nacional de Ética em Pesquisa; Canada: Hamilton Integrated Research Ethics Board; Kuwait: Ministry of Health Standing Committee for Coordination of Health and Medical Research; Pakistan: Maroof Institutional Review Board; Saudi Arabia: Ministry of National Guard Health Affairs Institutional Review Board: United Kingdom: Hampshire B Research Ethics Committee; United States: Institutional Review Board of the Nebraska Medical Centre. The results of this trial will inform clinical practice and guidelines worldwide.
TRIAL REGISTRATION NUMBER: NCT03374800.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
BMJ open - 13(2023), 11 vom: 15. Nov., Seite e075588 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.11.2023 Date Revised 24.11.2023 published: Electronic ClinicalTrials.gov: NCT03374800 Citation Status MEDLINE |
|---|
| doi: |
10.1136/bmjopen-2023-075588 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364595957 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364595957 | ||
| 003 | DE-627 | ||
| 005 | 20231226211158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/bmjopen-2023-075588 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1215.xml |
| 035 | |a (DE-627)NLM364595957 | ||
| 035 | |a (NLM)37968012 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deane, Adam M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a REVISE |b Re-Evaluating the Inhibition of Stress Erosions in the ICU: a randomised trial protocol |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.11.2023 | ||
| 500 | |a Date Revised 24.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03374800 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a INTRODUCTION: The Re-Evaluating the Inhibition of Stress Erosions (REVISE) Trial aims to determine the impact of the proton pump inhibitor pantoprazole compared with placebo on clinically important upper gastrointestinal (GI) bleeding in the intensive care unit (ICU), 90-day mortality and other endpoints in critically ill adults. The objective of this report is to describe the rationale, methodology, ethics and management of REVISE | ||
| 520 | |a METHODS AND ANALYSIS: REVISE is an international, randomised, concealed, stratified, blinded parallel-group individual patient trial being conducted in ICUs in Canada, Australia, Saudi Arabia, UK, US, Kuwait, Pakistan and Brazil. Patients≥18 years old expected to remain invasively mechanically ventilated beyond the calendar day after enrolment are being randomised to either 40 mg pantoprazole intravenously or an identical placebo daily while mechanically ventilated in the ICU. The primary efficacy outcome is clinically important upper GI bleeding within 90 days of randomisation. The primary safety outcome is 90-day all-cause mortality. Secondary outcomes include rates of ventilator-associated pneumonia, Clostridioides difficile infection, new renal replacement therapy, ICU and hospital mortality, and patient-important GI bleeding. Tertiary outcomes are total red blood cells transfused, peak serum creatinine level in the ICU, and duration of mechanical ventilation, ICU and hospital stay. The sample size is 4800 patients; one interim analysis was conducted after 2400 patients had complete 90-day follow-up; the Data Monitoring Committee recommended continuing the trial | ||
| 520 | |a ETHICS AND DISSEMINATION: All participating centres receive research ethics approval before initiation by hospital, region or country, including, but not limited to - Australia: Northern Sydney Local Health District Human Research Ethics Committee and Mater Misericordiae Ltd Human Research Ethics Committee; Brazil: Comissão Nacional de Ética em Pesquisa; Canada: Hamilton Integrated Research Ethics Board; Kuwait: Ministry of Health Standing Committee for Coordination of Health and Medical Research; Pakistan: Maroof Institutional Review Board; Saudi Arabia: Ministry of National Guard Health Affairs Institutional Review Board: United Kingdom: Hampshire B Research Ethics Committee; United States: Institutional Review Board of the Nebraska Medical Centre. The results of this trial will inform clinical practice and guidelines worldwide | ||
| 520 | |a TRIAL REGISTRATION NUMBER: NCT03374800 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adult gastroenterology | |
| 650 | 4 | |a Adult intensive & critical care | |
| 650 | 4 | |a Bleeding disorders & coagulopathies | |
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Gastroduodenal disease | |
| 650 | 7 | |a Pantoprazole |2 NLM | |
| 650 | 7 | |a D8TST4O562 |2 NLM | |
| 650 | 7 | |a Proton Pump Inhibitors |2 NLM | |
| 700 | 1 | |a Alhazzani, Waleed |e verfasserin |4 aut | |
| 700 | 1 | |a Guyatt, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Finfer, Simon |e verfasserin |4 aut | |
| 700 | 1 | |a Marshall, John C |e verfasserin |4 aut | |
| 700 | 1 | |a Myburgh, John |e verfasserin |4 aut | |
| 700 | 1 | |a Zytaruk, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Hardie, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Saunders, Lois |e verfasserin |4 aut | |
| 700 | 1 | |a Knowles, Serena |e verfasserin |4 aut | |
| 700 | 1 | |a Lauzier, Francois |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Marianne J |e verfasserin |4 aut | |
| 700 | 1 | |a English, Shane |e verfasserin |4 aut | |
| 700 | 1 | |a Muscedere, John |e verfasserin |4 aut | |
| 700 | 1 | |a Arabi, Yaseen |e verfasserin |4 aut | |
| 700 | 1 | |a Ostermann, Marlies |e verfasserin |4 aut | |
| 700 | 1 | |a Venkatesh, Balasubramanian |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Thabane, Lehana |e verfasserin |4 aut | |
| 700 | 1 | |a Billot, Laurent |e verfasserin |4 aut | |
| 700 | 1 | |a Heels-Ansdell, Diane |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Fares, Abdulrahman A |e verfasserin |4 aut | |
| 700 | 1 | |a Hammond, Naomi E |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, R |e verfasserin |4 aut | |
| 700 | 1 | |a Rajbhandari, Dorrilyn |e verfasserin |4 aut | |
| 700 | 1 | |a Poole, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Johnson, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Iqbal, Mobeen |e verfasserin |4 aut | |
| 700 | 1 | |a Reis, Gilmar |e verfasserin |4 aut | |
| 700 | 1 | |a Xie, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Cook, Deborah J |e verfasserin |4 aut | |
| 700 | 0 | |a Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMJ open |d 2012 |g 13(2023), 11 vom: 15. Nov., Seite e075588 |w (DE-627)NLM215724372 |x 2044-6055 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:11 |g day:15 |g month:11 |g pages:e075588 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/bmjopen-2023-075588 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 11 |b 15 |c 11 |h e075588 | ||